A case of advanced hepatocellular carcinoma with portal vein tumor thrombus refractory to epirubicin that showed marked decrease in tumor markers after transcatheter arterial infusion with miriplatin

Case Reports in Oncology

Volumn 4, Issue 2, 2011, Pages 327-335

  Nishikawa, Hiroki ^a   Inuzuka, Tadashi ^a   Takeda, Haruhiko ^a   Nakajima, Jun ^a   Sakamoto, Azusa ^a   Henmi, Sinichiro ^a   Ishikawa, Tetsurou ^a   Saito, Sumio ^a   Kita, Ryuichi ^a   Kimura, Toru ^a   Osaki, Yukio ^a   Koshikawa, Yorimitsu ^a  

^a OSAKA RED CROSS HOSPITAL   (Japan)

Author keywords

Epirubicin; Hepatocellular carcinoma; Miriplatin; Tumor marker

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; EPIRUBICIN; IODINATED POPPYSEED OIL; MIRIPLATIN; TUMOR MARKER;

ABSENCE OF SIDE EFFECTS; ADVANCED CANCER; AGED; ARTICLE; CANCER SIZE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DIGITAL SUBTRACTION ANGIOGRAPHY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEVER; HEPATIC ARTERY; HEPATITIS C VIRUS; HUMAN; LIVER CELL CARCINOMA; MALE; PORTAL VEIN; PRIORITY JOURNAL; TREATMENT OUTCOME; TUMOR THROMBUS;

EID: 80052762860     PISSN: None     EISSN: 16626575     Source Type: Journal    
DOI: 10.1159/000330106     Document Type: Article

References (14)

1. Maeda M, Uchida NA, Sasaki T: Liposoluble platinum (II) complexes with antitumor activity. Jpn J Cancer Res 1986;77:523-525. (Pubitemid 16061614)
2. Kishimoto S, Noguchi T, Yamaoka T, Fukushima S, Takeuchi Y: Antitumor effects of a novel lipophilic platinum complex (SM-11355) against a slowly growing rat hepatic tumor after intra-hepatic arterial administration. Biol Pharm Bull 2000;23:344-348. (Pubitemid 30187283)
3. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T, Chiba N, et al: Intra-arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of tumors implanted in rat livers by inducing platinum-DNA adducts to form and massive apoptosis. Cancer Chemother Pharmacol 2009;64:473-483.
4. Hanada M, Baba A, Tsutsumishita Y, Noguchi T, Yamaoka T: Intra-arterial administration with miriplatin suspended in an oily lymphographic agent inhibits the growth of human hepatoma cells orthotopically implanted in nude rats. Cancer Sci 2009;100:189-194.
5. Leung WT, Shiu WC, Leung N, Chan M, Tao M, Li AK, et al: Treatment of inoperable hepatocellular carcinoma by intra-arterial lipiodol and 4'-epidoxorubicin. Cancer Chemother Pharmacol 1992;29:401-404.
6. Kinami Y, Miyazaki Y: The superselective and selective one shot methods for treating inoperable cancer of the liver. Cancer 1978;41:1720-1727. (Pubitemid 8335379)
7. Kraybill WG, Harrison M, Sasaki T, Fletcher WS: Regional intra-arterial infusion of adriamycin in the treatment of cancer. Surg Gynecol Obstet 1977;144:335-538.
8. Ansfield FJ, Ramirez G, Davis HL Jr, Wirtanen GW, Johnson RO, Bryan GT, et al: Further clinical studies with intrahepatic arterial infusion with 5-fluorouracil. Cancer 1975;36:2413-2417.
9. Buchwald H, Grage TB, Vassilopoulos PP, Rohde TD, Varco RL, Blackshear PJ: Intraarterial infusion chemotherapy for hepatic carcinoma using a totally implantable infusion pump. Cancer 1980;45:866-869. (Pubitemid 10129834)
10. Ichikawa W, Togo S, Osanai T, Miyanaga T, Sawai S, Yamashita T, et al: Clinical study on the effect of intraarterial injection of mitoxantrone-lipiodol emulsion for hepatocellular carcinoma. Gan To Kagaku Ryoho 1994;21:2212-2214. (Pubitemid 24331757)
11. Shibata J, Fujiyama S, Sato T, Kishimoto S, Fukushima S, Nakano M: Hepatic arterial injection chemotherapy with cisplatin suspended in an oily lymphographic agent for hepatocellular carcinoma. Cancer 1989;64:1586-1594. (Pubitemid 19251124)
12. Okusaka T, Okada S, Ueno H, Ikeda M, Yishimori M, Shimada K, et al: Evaluation of the therapeutic effect of transcatheter arterial embolization for hepatocellular carcinoma. Oncology 2000;58:293-299. (Pubitemid 30265338)
13. Takayasu K, Arii S, Matsuo N, Yoshikawa M, Ryu M, Takasaki K, et al: Comparison of CT findings with resected specimens after chemoembolization with iodized oil for hepatocellular carcinoma. Am J Roentgenol 2000;175:699-704.
14. Kudo M, Kubo S, Takayasu K, Sakamoto M, Tanaka M, Ikai I, et al: Response Evaluation Criteria in Cancer of the Liver (RECICL) proposed by the Liver Cancer Study Group of Japan (2009 revised version). Hepatol Res 2010;40:686-692.